MedPath

Ceftibuten

Generic Name
Ceftibuten
Brand Names
Cedax
Drug Type
Small Molecule
Chemical Formula
C15H14N4O6S2
CAS Number
97519-39-6
Unique Ingredient Identifier
IW71N46B4Y

Overview

Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

Background

Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

Indication

Indicated for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

Associated Conditions

  • Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)
  • Acute Otitis Media (AOM)
  • Acute Sinusitis
  • Acute Tracheobronchitis
  • Bacterial Infections
  • Bacterial Pneumonia
  • Lower Respiratory Tract Infection (LRTI)
  • Lower Respiratory Tract Infection (LRTI) caused by susceptible bacteria
  • Pharyngitis
  • Skin and Soft Tissue Infections (SSTIs)
  • Streptococcal Pharyngitis
  • Superinfection bacterial
  • Tonsillitis
  • Tonsillitis streptococcal
  • Upper Respiratory Tract Infection
  • Upper Respiratory Tract Infection caused by susceptible bacteria
  • Urinary Tract Infection caused by susceptible bacteria
  • Bacterial otitis media
  • Uncomplicated Lower Respiratory Tract Infection (LRTI)
  • Uncomplicated Upper Respiratory Tract Infection
  • Uncomplicated Urethritis gonococcal

FDA Approved Products

Cedax
Manufacturer:Sciele Pharma, Inc.
Route:ORAL
Strength:400 mg in 1 1
Approved: 2010/01/12
NDC:59630-820
Cedax
Manufacturer:Sciele Pharma, Inc.
Route:ORAL
Strength:18 mg in 1 mL
Approved: 2010/01/12
NDC:59630-821

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath